94 related articles for article (PubMed ID: 32234881)
1. Role of FOXO3A in Trastuzumab Combination Chemotherapy in Esophageal Squamous Cell Carcinoma.
Takahashi M; Fukuda K; Saikawa Y; Nakamura R; Wada N; Kawakubo H; Takeuchi H; Kitagawa Y
Anticancer Res; 2020 Apr; 40(4):1921-1930. PubMed ID: 32234881
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
[TBL] [Abstract][Full Text] [Related]
3. HERG1 promotes esophageal squamous cell carcinoma growth and metastasis through TXNDC5 by activating the PI3K/AKT pathway.
Wang H; Yang X; Guo Y; Shui L; Li S; Bai Y; Liu Y; Zeng M; Xia J
J Exp Clin Cancer Res; 2019 Jul; 38(1):324. PubMed ID: 31331361
[TBL] [Abstract][Full Text] [Related]
4. Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma
Song M; Liu X; Liu K; Zhao R; Huang H; Shi Y; Zhang M; Zhou S; Xie H; Chen H; Li Y; Zheng Y; Wu Q; Liu F; Li E; Bode AM; Dong Z; Lee MH
Mol Cancer Ther; 2018 Jul; 17(7):1540-1553. PubMed ID: 29695636
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
[TBL] [Abstract][Full Text] [Related]
7. RIT1 suppresses esophageal squamous cell carcinoma growth and metastasis and predicts good prognosis.
Feng YF; Lei YY; Lu JB; Xi SY; Zhang Y; Huang QT; Wu QL; Wang F
Cell Death Dis; 2018 Oct; 9(11):1085. PubMed ID: 30348939
[TBL] [Abstract][Full Text] [Related]
8. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma.
Mizumoto A; Ohashi S; Kamada M; Saito T; Nakai Y; Baba K; Hirohashi K; Mitani Y; Kikuchi O; Matsubara J; Yamada A; Takahashi T; Lee H; Okuno Y; Kanai M; Muto M
J Gastroenterol; 2019 Aug; 54(8):687-698. PubMed ID: 30737573
[TBL] [Abstract][Full Text] [Related]
10. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
11. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1.
Chang ZW; Jia YX; Zhang WJ; Song LJ; Gao M; Li MJ; Zhao RH; Li J; Zhong YL; Sun QZ; Qin YR
J Exp Clin Cancer Res; 2018 Mar; 37(1):56. PubMed ID: 29530057
[TBL] [Abstract][Full Text] [Related]
12. A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.
Papadakis E; Robson N; Yeomans A; Bailey S; Laversin S; Beers S; Sayan AE; Ashton-Key M; Schwaiger S; Stuppner H; Troppmair J; Packham G; Cutress R
Oncotarget; 2016 Apr; 7(14):18851-64. PubMed ID: 26958811
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways.
Aghazadeh S; Yazdanparast R
Apoptosis; 2016 Nov; 21(11):1302-1314. PubMed ID: 27651367
[TBL] [Abstract][Full Text] [Related]
14. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
15. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
[TBL] [Abstract][Full Text] [Related]
17. Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.
Espelin CW; Leonard SC; Geretti E; Wickham TJ; Hendriks BS
Cancer Res; 2016 Mar; 76(6):1517-27. PubMed ID: 26759238
[TBL] [Abstract][Full Text] [Related]
18. Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway.
Zhang W; Bhagwath AS; Ramzan Z; Williams TA; Subramaniyan I; Edpuganti V; Kallem RR; Dunbar KB; Ding P; Gong K; Geurkink SA; Beg MS; Kim J; Zhang Q; Habib AA; Choi SH; Lapsiwala R; Bhagwath G; Dowell JE; Melton SD; Jie C; Putnam WC; Pham TH; Wang DH
Mol Cancer Ther; 2021 Oct; 20(10):1904-1915. PubMed ID: 34376577
[TBL] [Abstract][Full Text] [Related]
19. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
Fang L; Wang H; Zhou L; Yu D
Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
[TBL] [Abstract][Full Text] [Related]
20. α-linolenic acid and docosahexaenoic acid, alone and combined with trastuzumab, reduce HER2-overexpressing breast cancer cell growth but differentially regulate HER2 signaling pathways.
Mason JK; Klaire S; Kharotia S; Wiggins AK; Thompson LU
Lipids Health Dis; 2015 Aug; 14():91. PubMed ID: 26282560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
